Please assess the completion status of the following clinical trial:

Trial Title: Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has provided written informed consent with HIPAA authorization before participating in the study, as has his/her responsible caregiver, if applicable.~* The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.~* The patient is at least 18 years of age at the time of consent.~* The patient has an ECOG performance status of Grade 0 - 2 \[8\].~* The patient has a clinical negative node status at the time of study entry.~* If of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.~* The patient is currently not participating in another investigational drug study.~Melanoma Patients~* The patient has a diagnosis of primary melanoma.~Breast Cancer Patients~* The patient has a diagnosis of primary breast cancer.~* Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.~Exclusion Criteria:~* The patient is pregnant or lactating;~* The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0);~* The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V.~Melanoma Patients~* The patient has a tumor with a Breslow depth less than 0.75mm.;~* Patients that have had preoperative chemotherapy, immunotherapy or radiation therapy;~* Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin;~* Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma;~* Patients who have undergone a wide excision for their primary melanoma (\>1 cm in dimension) or complex reconstruction (rotation, free flap or skin graft of any type).~Breast Cancer Patients~* The patient has bilateral primary breast cancers or multiple tumors within their breast;~* Patients that have had prior surgical procedures such as breast implants, reduction mammoplasty or axillary surgery;~* Patients scheduled for bilateral mastectomy for any reason;~* Patients that have had preoperative radiation therapy to the affected breast or axilla

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lymphoseek, Lymphatic mapping, Injection (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).